

## Increased expression of $\alpha$ -synuclein is a primary cause of PD

A limited increase in WT  $\alpha$ -synuclein expression can cause both familial and sporadic forms of PD:

- Duplications and triplications of the WT *SNCA* gene lead to autosomal dominant PD.
- Polymorphisms in the *SNCA* locus increasing *SNCA* transcription confer high risk for sporadic PD.
- $\alpha$ -synuclein mRNA levels are increased in dopaminergic neurons of sporadic PD patients.
- Overexpression of WT  $\alpha$ -synuclein leads to neurodegenerative syndromes in animal models.

However, the transcriptional regulation of  $\alpha$ -synuclein is poorly understood.


# TRIM17, a crucial E3 ubiquitin-ligase for neuronal apoptosis

★ TRIM17 is highly induced in early apoptotic neurons


Desagher et al. (2005) *J. Biol. Chem.* 280: 5693-5702.

★ TRIM17 is both sufficient and necessary for neuronal apoptosis

Lassot et al. (2010) *Cell Death Differ.* 17: 1928-1941



primary cultures of cerebellar granule neurons




★ TRIM17 belongs to the TRIM family of E3 ubiquitin-ligases

# ZSCAN21, a transcription factor that regulates $\alpha$ -synuclein expression

Yeast two hybrid screen (Hybrigenics) for proteins binding to TRIM17:

- ➡ 19 independent partner candidates, including ZSCAN21 and TRIM41




★ ZSCAN21 is involved in the transcriptional regulation of  $\alpha$ -synuclein


(Clough et al. 2009 *J. Neurochem* 110: 1479-149; Wright et al. 2013 *Mol Cell Neurosci* 57: 33-41;  
Dermentzaki et al. 2016 *J Biol Chem* 291: 8756-8772)

# TRIM17 and ZSCAN21 interact with each other and increase $\alpha$ -synuclein expression

## co-immunoprecipitation




## quantitative PCR using SH-SY5Y cells after co-transfection with GFP and FACS sorting




# Regulation of ubiquitination/degradation of ZSCAN21 by TRIM17

## ubiquitination levels in cells


### purification on nickel beads



## pulse-chase



## co-immunoprecipitation




- Overexpression of TRIM17 does not significantly modify ZSCAN21 ubiquitination/degradation.


→ TRIM17 is not an E3 ubiquitin-ligase for ZSCAN21.

# Regulation of ubiquitination/degradation of ZSCAN21 by TRIM41 and TRIM17


## ubiquitination levels in cells



## pulse-chase




## co-immunoprecipitation




- Overexpression of TRIM17 does not significantly modify ZSCAN21 ubiquitination/degradation.
- TRIM17 is not an E3 ubiquitin-ligase for ZSCAN21.
- TRIM41 strongly increases ZSCAN21 ubiquitination/degradation in cells.
- The effects of TRIM41 are abolished by TRIM17.

# TRIM41 is an E3 ubiquitin-ligase for ZSCAN21 that targets it for degradation


## Proximity Ligation Assay (Duolink)




## Silencing of TRIM41 stabilizes ZSCAN21




# TRIM17 inhibits TRIM41-mediated ubiquitination/degradation of ZSCAN21



## *in vitro* auto-ubiquitination




## co-immunoprecipitation






→ by reducing both the E3 ubiquitin-ligase activity of TRIM41 and the interaction between ZSCAN21 and TRIM41

# Working hypothesis: TRIM17 stabilizes ZSCAN21 by inhibiting TRIM41




# Regulation of $\alpha$ -synuclein expression by TRIM17, TRIM41 and ZSCAN21


quantitative PCR , SH-SY5Y cells after transduction with specific shRNAs



- 1: shRNA ctrl
- 2: shRNA ZSCAN21#1
- 3: shRNA ZSCAN21#2
- 4: shRNA TRIM17#1
- 5: shRNA TRIM17#2
- 6: shRNA TRIM41#1
- 7: shRNA TRIM41#2






# SNCA, TRIM17, ZSCAN21 and TRIM41 expression in midbrains of MPTP-treated mice




# Genetic variations in *TRIM17*, *TRIM41* and *ZSCAN21* in PD patients

Sequencing of *TRIM17*, *TRIM41* and *ZSCAN21* in 200 index cases from families with autosomal dominant Parkinson's disease and 200 healthy controls (collaboration with Suzanne Lesage, ICM).




# ZSCAN21 p.V5I and TRIM41 p.534C variants co-segregate with Parkinson's disease


Family A: ZSCAN21 p.V5I



Family B: ZSCAN21 p.V5I




Family C: TRIM41 p.R534C



AE: age at examination  
AO: age at onset

→ A dysregulation of the TRIM17/TRIM41/ZSCAN21 pathway may be involved in PD.


# The variant ZSCAN21 p.V5I is more stable




→ ZSCAN21 p.V5I may increase the expression of  $\alpha$ -synuclein in patients by being more stable.

# The variant TRIM41 p.R534C has a lower affinity for ZSCAN21

## *in vitro* auto-ubiquitination




## co-immunoprecipitation




→ TRIM41 p.R534C may increase the expression of  $\alpha$ -synuclein in patients by targeting ZSCAN21 for degradation with a lower efficiency.

# A dysregulation of the TRIM41/TRIM17/ZSCAN21 pathway may be involved in PD




## Therapeutic perspectives

## normal conditions



## pathological conditions



# Acknowledgements



The team “Molecular Mechanisms of Apoptosis Regulation”

*current members:*

- Solange Desagher
- Iréna Lassot
- Stéphan Mora
- Meenakshi Basu
- Alina Kozoriz
- Sahra Tasdelen

*former members:*

- Cecilia Marelli
- Barbara Zieba
- Emmanuelle Coque
- Piotr Bossowski
- Barbara Mojsa
- Anne-Sophie Dumé
- Alessandra Damiano
- Caroline Soulet

Collaborators:



ICM (Paris):

Suzanne Lesage and colleagues  
(Olga Corti's laboratory)



VHIR (Barcelona):

Miquel Vila and colleagues

Funding:

